| Familial hypercholesterolemia - heterozygous
Leqvio vs Nextletol
Side-by-side clinical, coverage, and cost comparison for familial hypercholesterolemia - heterozygous.Deep comparison between: Leqvio vs Nexletol with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsNexletol has a higher rate of injection site reactions vs Leqvio based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Nexletol but not Leqvio, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Leqvio
Nexletol
At A Glance
SC injection
Every 6 months (after initial doses)
PCSK9 siRNA
Oral
Daily
ACL inhibitor
Indications
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
- Homozygous Familial Hypercholesterolemia
- Hypercholesterolemia
- Familial hypercholesterolemia - heterozygous
Dosing
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous, Homozygous Familial Hypercholesterolemia 284 mg SC injection initially, again at 3 months, then every 6 months; administered by a healthcare professional into abdomen, upper arm, or thigh.
Hypercholesterolemia, Familial hypercholesterolemia - heterozygous 180 mg orally once daily with or without food; analyze lipid levels within 8 to 12 weeks after initiation.
Contraindications
- Prior serious hypersensitivity reaction to inclisiran or any excipient in LEQVIO (including anaphylaxis and angioedema)
- Prior serious hypersensitivity reaction to bempedoic acid or any excipient in NEXLETOL
Adverse Reactions
Most common (>=3%) Injection site reaction, arthralgia, bronchitis
Postmarketing Anaphylaxis, angioedema, rash, pruritus, urticaria
Most common (>=2%) Upper respiratory tract infection, muscle spasms, hyperuricemia, back pain, abdominal pain or discomfort, bronchitis, pain in extremity, anemia, elevated liver enzymes
Serious Hyperuricemia, tendon rupture
Postmarketing Angioedema, wheezing, rash, urticaria
Pharmacology
PCSK9 siRNA; inclisiran is a double-stranded siRNA conjugated with GalNAc that directs catalytic breakdown of PCSK9 mRNA in hepatocytes, increasing LDL-C receptor recycling and expression on the hepatocyte cell surface to reduce circulating LDL-C.
Bempedoic acid is an ACL inhibitor that lowers LDL-C by inhibiting cholesterol synthesis in the liver upstream of HMG-CoA reductase; it requires CoA activation by ACSVL1 (expressed primarily in the liver) and upregulates LDL receptors to reduce circulating LDL-C.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Leqvio
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Nexletol
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (11/12) · Qty limit (11/12)
UnitedHealthcare
Leqvio
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Nexletol
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (6/8) · Qty limit (6/8)
Humana
Leqvio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (2/3)
Nexletol
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Hypercholesterolemia - Medicare Access
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Nexletol.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LeqvioView full Leqvio profile
NexletolView full Nexletol profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.